| Name | Title | Contact Details |
|---|---|---|
Danielle Gray |
Executive Vice President and Global Chief Legal Officer | Profile |
Danielle Gray |
Executive Vice President and Global Chief Legal Officer | Profile |
Matthew D`Ambrosio |
Senior Vice President, Global Chief Compliance and Ethics Officer, and Interim Global Chief Legal Officer | Profile |
Matthew D`Ambrosio |
Senior Vice President, Global Chief Compliance and Ethics Officer and Interim Chief Legal Officer | Profile |
Matthew D'Ambrosio |
Senior Vice President, Global Chief Compliance and Ethics Officer | Profile |
At SI Group, we create smart chemistry that solves global challenges and makes great things possible. We create smart chemistry that solves global challenges and makes great things possible. SI Group is a performance additives and intermediates business. We offer a broad array of products that feed into diverse applications including pharmaceuticals; plastics; oil and gas; and tires, among many others. We create solutions that provide formulators and manufacturers with the ability to increase efficacy, efficiency, productivity, and purity in countless industrial and consumer goods. Our company unites us. So do our values and the approach that we bring into the workplace each day.
Confab Laboratories Inc. is a Saint-Hubert, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Leading North American Specialty Pharmaceutical Company focused on hematology, rheumatology, auto-immune disease, specialty oncology and pediatrics.
UltraFiltronics Corp is a Randolph, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ohr Pharmaceutical, Inc. (OHRP) is an ophthalmology research and development company. The company`s lead product, Squalamine (OHR-102), is currently being studied as an eye drop formulation in several company sponsored and investigator sponsored Phase II clinical trials for various back-of-the-eye diseases, including the wet form of age-related macular degeneration, retinal vein occlusion, diabetic macular edema, and proliferative diabetic retinopathy. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery.